Newsletters

[British Journal of Cancer] Established and primary prostate cancer lines were treated with the cFLIP inhibitor, OH14, in combination with recombinant TRAIL to investigate changes in viability and colony forming potential.

[Scientific Reports] Functional studies demonstrated that knockdown of the lnc-ALX1-2 gene cluster suppresses proliferation, migration, and invasion in PC-3 M-1E8 cells, with lnc-ALX1-2:10 showing the most prominent effect.

[Journal of Translational Medicine] ZNF692 was highly expressed in prostate cancer tissues and was positively correlated with the clinical pathological stage. Overexpression of ZNF692 promotes the proliferation, migration, and invasion of prostate cancer cells, while knockdown inhibits them.

[Molecular Cancer] Scientists identified a mechanism linking metabolism, epigenetics, and a KDM5B/AR feedback loop in drug resistance.

[Cancer Research] Researchers investigated physical and molecular interactions between poorly differentiated prostate cancer cells with exocrine or neuroendocrine features, which recapitulated pre-existing human CRPC-like cells, and decellularized prostate extracellular matrix.

[Johnson & Johnson] Johnson & Johnson announced preliminary results from a Phase Ib study evaluating pasritamig (JNJ-78278343), a first-in-class bispecific T cell engaging antibody, in combination with docetaxel in patients with metastatic CRPC.

[Pfizer Inc. ] Pfizer Inc., announced that the US FDA has granted full approval to BRAFTOVI^® in combination with cetuximab and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation based on results from the global Phase III BREAKWATER trial.

[Cancer Grand Challenges (Business Wire)] Cancer Grand Challenges, a global initiative co-founded by the National Cancer Institute in the US and Cancer Research UK, announced a major $125m commitment to propel cancer research into uncharted territory.

[Nature Communications] Investigators set out to determine the molecular targets and pathways controlled by Foxl1 during intestinal villification

[Science Advances] Scientists adapted and applied two high-throughput techniques, SNP-STARR-seq and Methyl-STARR-seq, to systematically evaluate the influence of 30,790 noncoding SNPs and more than 134,000 CpG sites on enhancer activity in primary and metastatic CRC cells.

[Cancer Research] Researchers revealed lactylation as a metabolic switch linking cancer glycolytic reprogramming to transcriptional rewiring and proposes targeting PKM2 lactylation to enhance the anti-tumor activity of bevacizumab in colorectal cancer.

[Redox Biology] The authors revealed that p53 induces ferroptosis in the presence of abundant polyunsaturated fatty acids (PUFAs). They uncovered that the availability of PUFAs is crucial for p53 to exert a pro-ferroptotic function in colorectal cancer.